GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a biotech company specializing in the treatment of rare endocrine diseases. Its stock price is driven by news of clinical trials of its oral drugs. The chart reflects investor confidence in the potential of its scientific platform.
Share prices of companies in the market segment - Pharma metabolism
Crinetics is a biotech company specializing in the treatment of rare endocrine diseases. We classify it in the pharmaceuticals (metabolism) sector, and the chart below reflects general trends and investor sentiment in this biotech sector.
Broad Market Index - GURU.Markets
Crinetics Pharmaceuticals is a biopharmaceutical company developing oral medications for the treatment of rare endocrine diseases. As a component of the GURU.Markets index, it represents the orphan disease sector. The chart below represents the entire market. See how Crinetics shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CRNX - Daily change in the company's share price Crinetics Pharmaceuticals
For Crinetics Pharmaceuticals, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Crinetics Pharmaceuticals, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with CRNX, which focuses on rare endocrine diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Crinetics is a biopharmaceutical company specializing in drugs for the treatment of rare endocrine diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Crinetics' stock price.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Crinetics Pharmaceuticals
Crinetics is a biotech company specializing in the treatment of rare endocrine diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Crinetics Pharmaceuticals, Inc. is a biotech company focused on developing drugs for the treatment of rare endocrine diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Crinetics Pharmaceuticals is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Crinetics Pharmaceuticals
Crinetics, a biopharmaceutical company specializing in rare endocrine diseases, has sharp monthly fluctuations, typical for biotech companies, reflecting the release of clinical trial data that could either confirm or refute the potential of its drugs.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Crinetics Pharmaceuticals is a biotech company specializing in the development of oral medications for the treatment of rare endocrine diseases and tumors. Their goal is to replace injections with convenient pills. The chart below illustrates the dynamics of the biotech sector, where a focus on rare diseases can bring great success.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Crinetics Pharmaceuticals is a biotech company developing drugs to treat rare endocrine disorders. Its shares move in sync with clinical trial news. The chart below shows overall market sentiment, but for Crinetics, its own scientific advances are far more important.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Crinetics Pharmaceuticals
For biopharmaceutical company Crinetics, weekly stock performance is the pulse of its scientific developments. The price reacts sharply to any news, from interim clinical trial data to regulatory announcements. This chart clearly illustrates how investor expectations in the field of innovative medicine change from week to week, driven by information.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
How unique is Crinetics' weekly performance compared to other pharmaceutical companies? This chart compares its short-term fluctuations, often driven by clinical trial news, with the overall sector trend. This helps us understand whether a sharp share price move is the result of a unique event or a reflection of overall sentiment in the biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Crinetics Pharmaceuticals lives by the rhythm of clinical trials, not economic cycles. This chart shows how its weekly performance can be out of sync with the broader market. Sharp movements in the company's stock are typically driven by internal development news, not by general market trends.
Market capitalization of the company, segment and market as a whole
CRNX - Market capitalization of the company Crinetics Pharmaceuticals
Crinetics Pharmaceuticals' market valuation reflects investors' bet on a scientific breakthrough. The company develops drugs to treat rare endocrine disorders, and its market cap is sensitive to clinical trial results. The chart illustrates the biotech company's journey from high hopes to potential commercial success.
CRNX - Share of the company's market capitalization Crinetics Pharmaceuticals within the market segment - Pharma metabolism
Crinetics Pharmaceuticals focuses on rare endocrine diseases. Its market capitalization in the biotech sector appears small, but reflects the high valuation of its innovative drug portfolio. The chart shows how clinical trial success affects its market share, demonstrating the potential to become a significant player in its narrow but important niche.
Market capitalization of the market segment - Pharma metabolism
The chart below reflects the total value of the biotech segment focused on metabolic diseases—an area of enormous promise and risk. Crinetics Pharmaceuticals is a prominent part of this ecosystem, where every change on the chart signals success or failure in drug discovery.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph reflects the market valuation of a scientific breakthrough. Each rise isn't speculation, but positive clinical trial data that brings the development of drugs for rare diseases closer. The line shows the growing economic weight of a single idea, capable of changing thousands of lives and capturing its share of the global market.
Book value capitalization of the company, segment and market as a whole
CRNX - Book value capitalization of the company Crinetics Pharmaceuticals
The material foundation of Crinetics Pharmaceuticals is not its factories, but its intellectual capital and laboratory equipment. The chart below converts the value of its unique developments and scientific instruments into financial terms. Its growth reflects progress in the development of new drugs for the treatment of metabolic and endocrine diseases.
CRNX - Share of the company's book capitalization Crinetics Pharmaceuticals within the market segment - Pharma metabolism
In the world of biopharmaceuticals, real assets aren't giant factories, but cutting-edge research laboratories and ultra-precise equipment. The chart reflects Crinetics' material contribution to the race for new drugs, demonstrating the share of the company's valuable research infrastructure for metabolic diseases.
Market segment balance sheet capitalization - Pharma metabolism
Crinetics Pharmaceuticals' value lies not in its plants, but in its molecules. As a biotech company, it invests in intellectual property and research, not in heavy equipment. Is this "lightweight" knowledge-based model typical of pharmaceuticals? The chart reveals just how capital-intensive the industry as a whole is.
Book value of all companies included in the broad market index - GURU.Markets
Unlike factories, Crinetics' assets are capital invested in science: laboratories, patents, and clinical trial data. Their book value is the financial expression of hope for a breakthrough in endocrinology. The chart below demonstrates the scale of these intellectual assets compared to other science-intensive companies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Crinetics Pharmaceuticals
Crinetics Pharmaceuticals has almost no tangible assets. Its balance sheet is mostly cash flowing from research. Its entire market capitalization is a bet by investors on the success of its R&D platform and future sales of drugs for rare diseases. The chart shows how hopes for a scientific breakthrough create value out of thin air.
Market to book capitalization ratio in a market segment - Pharma metabolism
Crinetics Pharmaceuticals is a biotech company whose primary value lies not in its buildings but in its intellectual property. This metric demonstrates how much its market valuation, based on the potential of its future drugs, exceeds its modest book value. It's a classic story for innovative pharmaceuticals.
Market to book capitalization ratio for the market as a whole
Crinetics Pharmaceuticals is a biotech company whose core value lies not in its buildings but in its scientific potential. This chart illustrates how the market values its future success in drug development. Investors are betting on intellectual property and research breakthroughs, so the market value can be a multiple of the book value of its assets.
Debts of the company, segment and market as a whole
CRNX - Company debts Crinetics Pharmaceuticals
Crinetics Pharmaceuticals operates in a field where the path from idea to drug development is long and expensive. For the biotech company, raising debt capital is a way to finance multi-year clinical trials without diluting equity in the early stages. This chart illustrates the financial strategy that allows the company to advance its innovative drugs.
Market segment debts - Pharma metabolism
Crinetics Pharmaceuticals is a clinical-stage biotech company focused on endocrine diseases. In this industry, the financial strategy differs dramatically from traditional sectors: debt can be a tool for funding lengthy and expensive research. This chart provides insight into the financial norms in the pharmaceutical industry, against which Crinetics is striving for future breakthroughs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a biotech company focused on developing drugs for rare endocrine diseases. The journey from idea to finished drug takes many years and hundreds of millions of dollars. This chart shows the extent to which the company finances its expensive research and development with debt, banking on future success.
Market segment debt to market segment book capitalization - Pharma metabolism
Crinetics Pharmaceuticals is focused on developing drugs for endocrine disorders, which requires massive and sustained investments in research. This chart allows us to evaluate the company's leverage strategy by comparing its R&D commitments to the overall book value of the entire biotech sector, reflecting the scale of its ambitions.
Debt to book value of all companies in the market
Crinetics Pharmaceuticals is a biotech company whose debt finances breakthrough but risky research. This chart compares its liabilities to the book value of the entire economy. This allows us to assess, on a macro scale, how aggressively the company is raising capital for growth, whether it is ahead or behind overall market trends.
P/E of the company, segment and market as a whole
P/E - Crinetics Pharmaceuticals
This figure for Crinetics Pharmaceuticals, a biopharmaceutical company, should be interpreted with caution. Since the company is in the development stage and may not have stable profits, its value is determined by expectations of future success. The chart reflects investors' belief in the potential of its drugs for treating endocrine disorders rather than an estimate of current revenue.
P/E of the market segment - Pharma metabolism
This metric represents the average valuation for the biotech sector in which Crinetics operates. In this industry, filled with research-stage companies, the average earnings valuation is often uninformative. However, it reflects the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark for understanding Crinetics' value.
P/E of the market as a whole
Crinetics Pharmaceuticals combats rare endocrine diseases by developing breakthrough oral medications. It's a science-intensive business, where advances in the lab can dramatically change a company's valuation. This chart shows how the market views innovative industries overall and whether Crinetics' valuation is unique.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Crinetics Pharmaceuticals
Crinetics Pharmaceuticals focuses on drugs for rare endocrine diseases. Since biotech companies often lack consistent profitability, this chart represents market expectations for the company's future clinical research success. It reflects investor confidence that the company's research and development will soon translate into commercially successful products.
%20P%2FE%20Crinetics%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Crinetics-Pharmaceuticals&v=1772658719391 "Chart of the company's future (projected) P/E Crinetics Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma metabolism
Crinetics Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare endocrine diseases and cancers. Their innovative approach is aimed at creating new therapeutics. This chart shows overall market sentiment towards the biotech sector, helping to assess Crinetics' potential compared to industry expectations.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772658719499 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Crinetics Pharmaceuticals develops drugs to treat rare endocrine disorders. The company's value is derived from investors' faith in its scientific platform and the success of its clinical trials. While overall market forecasts can be volatile, Crinetics operates at its own pace, driven by news from the lab and regulators.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772658719507 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a biopharmaceutical company focused on developing drugs for rare endocrine diseases. Because its drugs are in various stages of clinical trials, financial results are highly dependent on R&D spending. This chart shows the points at which R&D investments lead to losses and, conversely, when successful developments begin to generate revenue.
Profit of companies in the market segment - Pharma metabolism
Crinetics Pharmaceuticals is a biotech company focused on developing drugs for rare endocrine diseases. This chart shows the overall profitability of its segment. As a clinical-stage company, Crinetics currently contributes negatively to overall profitability due to high R&D costs. However, its research successes are a potential driver of future growth for the entire industry.
Overall market profit
Crinetics Pharmaceuticals develops drugs to treat rare endocrine disorders. Unlike industrial giants, its success depends not on the economic cycle but on laboratory breakthroughs and regulatory approvals. This chart illustrates the overall corporate dynamics that can make the success of biotech companies like Crinetics appear to be at odds with the market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a biotech company developing drugs for the treatment of rare endocrine diseases. Currently in clinical trials, its future profits are entirely dependent on the success of its developments. This chart demonstrates analysts' confidence in the potential of its drug portfolio and the possibility of their future commercialization following regulatory approval.
%20profit%20of%20the%20company%20Crinetics%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Crinetics-Pharmaceuticals&v=1772658719737 "Graph of future (projected) profit of the company Crinetics Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Crinetics Pharmaceuticals is a biopharmaceutical company focused on developing drugs for rare endocrine diseases. This chart shows profitability forecasts for the entire segment. It helps assess how optimistic the market is about the prospects for the biotech industry, which develops innovative treatments, within which Crinetics is developing its products.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772658719748 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Crinetics Pharmaceuticals develops innovative drugs for the treatment of rare endocrine diseases. While biotech companies often follow their own trajectory, overall market profit expectations influence the investment climate. The positive outlook reflected in these data means capital is readily available for breakthrough research, allowing companies like Crinetics to advance medicine.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772658719887 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical-stage biotech company focused on rare diseases. Because it may not yet have stable sales revenue, the price-to-sales ratio is used to assess its future potential. The chart shows how the market values the initial sales dollars, factoring in expectations for the success of its innovative drugs.
P/S market segment - Pharma metabolism
Crinetics Pharmaceuticals is a clinical-stage biotech focused on endocrine diseases. Its current revenue is minimal, but its valuation reflects investors' confidence in the future success of its drugs. The chart helps illustrate how high these expectations are compared to other companies in the sector, where potential is often valued above current sales.
P/S of the market as a whole
Crinetics Pharmaceuticals focuses on rare endocrine diseases, and its revenue is entirely dependent on the success of clinical trials and future drug sales. The valuation of such companies often outpaces actual revenue. This chart helps understand the general revenue multiple the market is willing to pay and, against this backdrop, assess investor expectations for the biotech sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical-stage biotech company whose value depends almost entirely on future success. This metric is particularly important because it reflects investor expectations for the approval and commercialization of its drugs. It measures not current revenue streams, but potential multibillion-dollar revenue streams from its innovations.
%20P%2FS%20Crinetics%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Crinetics-Pharmaceuticals&v=1772658720112 "The graph of the company's future (projected) P/S Crinetics Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma metabolism
Crinetics Pharmaceuticals is a biotech company focused on rare endocrine diseases. Its valuation is based on expectations of future sales from its pipeline. This chart compares market expectations for Crinetics' commercial potential with those of other pharmaceutical companies, providing insight into investor confidence in its scientific developments and future market success.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772658720206 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Crinetics Pharmaceuticals develops drugs to treat rare endocrine disorders. The success of such innovative companies is a bet on a scientific breakthrough that could radically change the market. This chart shows revenue expectations for the entire market and helps understand whether capital is currently willing to invest in long-term and risky biotech projects.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772658720372 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating rare endocrine diseases. This chart shows its revenue, which at this stage is generated not from direct drug sales but primarily from partnership agreements and licensing deals. Steady revenue growth will begin after the drugs are approved and launched.
Sales of companies in the market segment - Pharma metabolism
Crinetics Pharmaceuticals is a biotech company focused on endocrine diseases. Since its key products are in development, this chart details its current revenue sources. It shows which partnerships and royalties form the financial basis for future clinical success.
Overall market sales
Crinetics Pharmaceuticals operates in a field where success depends not on the overall market, but on scientific breakthroughs. While this chart depicts economic cycles, Crinetics' revenue is driven by clinical trial results and approvals of new drugs for rare diseases, making it independent of overall consumer sentiment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Crinetics Pharmaceuticals
Crinetics Pharmaceuticals' future sales trends are critically important, as the company specializes in drugs for rare endocrine disorders. This chart shows analyst consensus estimates for the commercial potential of its developments, demonstrating whether experts believe the new drugs will be successfully launched and in demand.
%20sales%20of%20the%20company%20Crinetics%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Crinetics-Pharmaceuticals&v=1772658720749 "Schedule of future (projected) sales of the company Crinetics Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma metabolism
Crinetics Pharmaceuticals focuses on treating rare endocrine diseases. The trend presented here represents the total revenue forecast for the entire metabolic drugs segment. This provides investors with insight into the marketability of this pharmaceutical segment, a key success factor for a highly specialized company like Crinetics.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772658720825 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Crinetics Pharmaceuticals develops drugs to treat rare endocrine disorders. Although demand for its products is less elastic, the overall economic situation, reflected in this chart, influences investor sentiment and funding levels in the biotech sector. Positive market expectations facilitate raising capital for further clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772658720874 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Crinetics Pharmaceuticals
For biopharmaceutical company Crinetics Pharmaceuticals, this chart is the story of its journey from innovation to market. It demonstrates how the company manages the enormous costs of drug research and development. The ability to convert revenue into profit directly depends on successful clinical trials and the future commercialization of its drugs.
Market segment marginality - Pharma metabolism
Crinetics Pharmaceuticals is focused on developing drugs for rare endocrine diseases, which requires significant investment in R&D. This chart provides an indication of the potential commercial viability of its future drugs. Exceeding industry profitability benchmarks will signal recognition of its innovation and its ability to carve out a niche.
Market marginality as a whole
Crinetics Pharmaceuticals is a biotech company focused on rare diseases. Its success depends not on the broader economic climate, but on laboratory breakthroughs and regulatory approvals. This overall profitability chart shows the market average, while Crinetics can create its own high-margin reality through unique patents.
Employees in the company, segment and market as a whole
Number of employees in the company Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a biotech company focused on rare endocrine diseases. Its staff consists primarily of researchers and clinicians. Team growth on this chart may signal progress in research, drug advancement to new stages of clinical trials, or preparation for commercial launch.
Share of the company's employees Crinetics Pharmaceuticals within the market segment - Pharma metabolism
For Crinetics Pharmaceuticals, which focuses on rare endocrine diseases, scientists are the primary driver of progress. This metric measures the company's influence not by market capitalization, but by the concentration of scientific talent. It demonstrates what proportion of the total number of specialists in this narrow pharmaceutical niche Crinetics brings together to create breakthrough treatments.
Number of employees in the market segment - Pharma metabolism
Crinetics Pharmaceuticals focuses on rare endocrine diseases. This chart illustrates the talent pool for metabolic and endocrinology pharmaceuticals. The growing number of specialists in this niche indicates an influx of investment in research, creating a favorable environment for breakthrough developments and clinical success at Crinetics.
Number of employees in the market as a whole
Crinetics Pharmaceuticals operates at the forefront of biotechnology, developing drugs for rare endocrine diseases. Unlike industrial giants, its staff includes highly qualified scientists and researchers. Its growth in headcount reflects not the general economic climate, but rather advances in science and investment in innovative medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals is a biotech company whose value lies not in its machines, but in the minds of its scientists and patents. A small team of researchers can discover a blockbuster drug worth billions. This chart shows how highly the market values their intellectual capital, where the value of a single idea, translated into a molecule, is distributed among a small team.
%20of%20the%20company%20Crinetics%20Pharmaceuticals%20(CRNX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Crinetics-Pharmaceuticals-CRNX&v=1772658721346 "Chart of market capitalization per employee (in thousands of dollars) of the company Crinetics Pharmaceuticals (CRNX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Crinetics is a clinical-stage biotech company focused on treating rare endocrine diseases. It doesn't yet have mass sales. Its entire value lies in its intellectual property and the potential of its R&D platform. This chart shows the industry average, which helps us understand the enormous premium the market places on each Crinetics scientist.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772658721361 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Crinetics Pharmaceuticals focuses on developing drugs for rare endocrine diseases. In biotech, the key value is created not by factories, but by the intellectual capital of scientists. This chart reflects investors' expectations for future discoveries: a high valuation per employee indicates faith in the potential of their research and future patents, which could change patients' lives.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772658721387 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Crinetics Pharmaceuticals (CRNX)
Crinetics is a biotech company focused on developing new drugs for endocrine disorders. At this stage, its business is focused on research and development, not sales. Therefore, this chart is likely to be in negative territory. It shows the "cost" of each employee in R&D investments as the company moves toward commercialization of its discoveries.
%20Chart%20Crinetics%20Pharmaceuticals%20(CRNX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Crinetics-Pharmaceuticals-CRNX&v=1772658721398 "Company Profit Per Employee (in thousands of dollars) Chart Crinetics Pharmaceuticals (CRNX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Crinetics is a biotech company specializing in rare metabolic and endocrine diseases. This chart shows the industry average for "Specialty Pharma." In this sector, the profit per employee benchmark is either deeply negative (at the R&D stage) or astronomically high (when a blockbuster drug is approved).
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772658721486 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Crinetics is a biotech company working on drugs for rare endocrine diseases. Here, value is created not by staff, but by scientific breakthroughs. This chart, showing the average dollar return per employee across the market, asks: how does the R&D sector, where Crinetics operates, compare to the average profitability per employee?
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772658721498 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals is a clinical-stage biotech company, so traditional revenue per employee isn't representative. The graph rather reflects potential: if the drug is approved, even a small team could generate colossal revenue, demonstrating the financial power of intellectual property in pharmaceuticals.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Crinetics-Pharmaceuticals-CRNX&v=1772658721746 "Sales chart per company employee Crinetics Pharmaceuticals (CRNX)")
Sales per employee in the market segment - Pharma metabolism
Crinetics Pharmaceuticals focuses on treating endocrine disorders. In biotech, where many companies are still in the R&D stage, productivity is difficult to measure. This chart shows the average revenue per employee by segment, reflecting the benchmark for commercially successful companies. It helps understand how productive Crinetics' staff is relative to its competitors.
Sales per employee for the market as a whole
Crinetics Pharmaceuticals is a biotech company focused on endocrine diseases. During the R&D phase, this metric is often unrepresentative: the company spends heavily on highly qualified scientists while generating almost no revenue. However, as the company commercializes its drugs, this metric should skyrocket, demonstrating a shift from research costs to revenue generation per employee.
Short shares by company, segment and market as a whole
Shares shorted by company Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals is a clinical-stage biotech whose value depends almost entirely on the success of trials of drugs for rare endocrine diseases. This chart shows the number of skeptics betting on failure. "Shorts" here are a direct bet that their key drugs will fail to demonstrate expected efficacy or face regulatory delays.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Crinetics-Pharmaceuticals-CRNX&v=1772658722025 "Short Shares Chart for the Company Crinetics Pharmaceuticals (CRNX)")
Shares shorted by market segment - Pharma metabolism
Crinetics Pharmaceuticals is a biotech company focused on treating metabolic diseases. Its success depends on trial results and regulatory approvals. This indicator summarizes short positions across the entire pharmaceutical sector. If investors are shorting the industry, it could signal upcoming regulatory tightening or a general lack of confidence in the sector, which puts pressure on even promising companies.
Shares shorted by the overall market
Crinetics (CRNX) is a clinical-stage biotech (endocrinology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives CRNX of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals is a clinical-stage biotech company. Its shares are extremely sensitive to trial news. This chart for CRNX can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks or a general aversion to risk in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Crinetics-Pharmaceuticals-CRNX&v=1772658722348 "RSI 14 indicator chart for the company's stock Crinetics Pharmaceuticals (CRNX)")
RSI 14 Market Segment - Pharma metabolism
Crinetics Pharmaceuticals is a biotech company specializing in the development of oral (tablet-based) drugs for the treatment of rare endocrine diseases. This chart shows the overall momentum in the endocrinology-focused biotech sector. It helps determine whether the entire segment is overheated by expectations of clinical success.
RSI 14 for the overall market
Crinetics Pharmaceuticals is a biotech company whose fate depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like CRNX are forced to struggle to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CRNX (Crinetics Pharmaceuticals)
Crinetics Pharmaceuticals is a biotech company focused on developing oral (tablet-based) drugs for the treatment of rare endocrine diseases. This chart shows the average analyst forecast, representing their collective bet on the success of clinical trials and the commercial potential of their niche drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CRNX-Crinetics-Pharmaceuticals&v=1772658722703 "A chart showing analyst consensus forecasts for the expected stock price. CRNX (Crinetics Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price CRNX (Crinetics Pharmaceuticals)
Crinetics is a biotech company specializing in developing oral (tablet-based) drugs for the treatment of rare endocrine diseases (such as acromegaly). This chart shows the difference between the consensus estimate and the price. It reflects analyst confidence in its R&D platform and its potential.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CRNX-Crinetics-Pharmaceuticals&v=1772658722892 "A chart showing the difference between the consensus forecast and the actual stock price. CRNX (Crinetics Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Crinetics Pharmaceuticals is a biotech company specializing in the development of oral medications (tablets) for the treatment of rare endocrine (hormonal) diseases. This chart shows analysts' overall expectations for the "metabolism" sector. It reflects whether experts believe breakthroughs are possible in this complex area of pharma.
Analysts' consensus forecast for the overall market share price
Crinetics Pharmaceuticals is a biotech company specializing in rare endocrine (hormone-related) diseases. They are developing oral medications where previously only injections were available. This chart shows overall market sentiment. For Crinetics, operating in a complex niche, it's important to consider how overall risk appetite (analyst sentiment) influences funding for their developments. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Crinetics Pharmaceuticals
Crinetics (CRNX) is a biotech company focused on developing oral (tablet-based) drugs for the treatment of rare endocrine diseases (acromegaly) currently treated with injections. This chart represents the R&D bet. It measures the market's confidence that their pills can successfully replace injectable treatments, which represents a huge market.
AKIMA Market Segment Index - Pharma metabolism
Crinetics is a biotech focused on rare endocrine diseases. The company develops new oral (tablet) drugs for the treatment of conditions caused by excess hormones (e.g., acromegaly). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does Crinetics' niche (endocrine) R&D focus differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Crinetics is a biotech company focused on rare endocrine diseases (hormonal disorders). It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to overall economic trends.
